Results 121 to 130 of about 44,402 (291)

H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab [PDF]

, 2019
LF Ensina, LK Arruda, RA Campos, RF Jardim Criado, Solange Oliveira Rodrigues Valle, Janaína Michelle Lima Melo, JCS Oliveira, SD Dortas, AP Cusato- Ensina, IC Camelo-Nunes, RC Agondi   +10 more
openalex   +1 more source

Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms

Allergy, EarlyView.
ABSTRACT Background Atopic diseases—including atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR), and asthma—are the most common chronic conditions in childhood and adolescence, affecting up to 30% of the global population. In Germany alone, more than 2.1 million children and adolescents are affected.
E. Hamelmann, B. Schaub, K. Beyer, K. Blümchen, M. Gerstlauer, M. V. Kopp, L. Lange, S. Lau, N. Maison, H. Ott, S. M. Schmidt, T. Spindler, C. Traidl‐Hoffmann, C. Vogelberg   +13 more
wiley   +1 more source

Metabolism of CYP2D6 substrate, antihistaminic mequitazine in DA rats.

, 1997
Katsunori Nakamura
openalex   +2 more sources

Considerations on third generation antihistamines [PDF]

, 2002
Stephen T. Holgate
openalex   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Determination of Antihistamine in Tablets Preparation by Fluorescence Quenching Method

, 2022
Aditya Singgih Raharjo, Asmiyenti Djaliasrin Djalil, Pri Iswati Utami   +2 more
openalex   +2 more sources

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

<em>In Vitro</em> Anticholinergic and Antihistaminic Activities of <em>Acorus Calamus</em> Linn. Leaves Extracts

, 2012
P Vijayapandia, V Annabathina, B SivaNagaSrikanth, V Manjunath, P Boggavarapu, AK Mohammed P, K RajendraPrasad, CT Kumarappan   +7 more
openalex   +2 more sources

Unveiling Rare Genetic Variants in DAB2IP: New Insights Into the Pathogenesis of Recurrent Angioedema

Allergy, EarlyView.
Maurizio Margaglione, Maria D'Apolito, Rosa Santacroce, Giorgia Cordisco, Francesco Arcoleo, Tiziana De Pasquale, Ilaria Puxeddu, Andrea Zanichelli, Mauro Cancian   +8 more
wiley   +1 more source

Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

Allergy, EarlyView.
Evaluation en vie Réelle de l'Allergo‐Prescription en Pratique (ERAPP) is a large, prospective, real‐world cohort of children and adults initiating named‐patient product sublingual immunotherapy (NPP‐SLIT) in France. More than 80% of patients reported a clinically meaningful, expectation‐anchored benefit (Patient Benefit Index ≥ 1) at 12–15 months. The
Davide Caimmi, Abdelilah Abouelfath, Régis Lassalle, Séverine Lignot‐Maleyran, Emmanuelle Bignon, Patrick Blin, Evangéline Clark, Julien Cottet, Laure Carcaillon‐Bentata, Pascal Demoly   +9 more
wiley   +1 more source